← Simulations Plus overview

Simulations Plus vs Veeva Systems: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Simulations Plus Inc (SLP)

Q3 2026
▲3▼1

Altaris buyout at $18.50 cash anchors SLP; old accounting probe resurfaces

  • Altaris to buy SLP for $375M all-cash Altaris agreed to acquire Simulations Plus for about $375 million, or $18.50 a share in cash — a 26% premium to the 60-day average price. The board unanimously approved it, with closing expected in late 2026. This sets a firm floor under the stock and is the main reason it trades near the deal price.

    The buyout is the single biggest force setting SLP's price now.

  • Agentic AI layer built with NVIDIA BioNeMo Simulations Plus is building an AI 'agent' layer for its Composer platform using NVIDIA's BioNeMo toolkit, expanding a May 2026 partnership. It aims to speed up drug-modeling workflows while keeping scientific results traceable. This supports the company's long-term technology story, though the pending buyout now matters more for the share price.

    It shows the technology value underpinning the company being acquired.

  • Q3 swing to profit on no impairment charge Simulations Plus reported Q3 net income of $3.58 million versus a $67.32 million loss a year earlier, which had included a $77.22 million write-down. Revenue rose 7% to $21.89 million, but adjusted earnings fell to $0.30 a share from $0.45. Profitability improved, yet the core business still shows pressure.

    It gives the latest financial health picture behind the buyout.

  • Investor investigation revives old accounting worries Johnson Fistel is investigating Simulations Plus over a 2025 revenue guidance cut, a large net loss, and the dismissal of auditor Grant Thornton, which flagged unresolved segment-reporting and internal-control issues. These are old disclosures, but the probe keeps the accounting overhang in view and is a real counterweight to the buyout news.

    It is the main risk factor that could complicate or delay the deal.

July 2026
▲3▼1

Altaris buyout at $18.50 cash anchors SLP; old accounting probe resurfaces

  • Altaris to buy SLP for $375M all-cash Altaris agreed to acquire Simulations Plus for about $375 million, or $18.50 a share in cash — a 26% premium to the 60-day average price. The board unanimously approved it, with closing expected in late 2026. This sets a firm floor under the stock and is the main reason it trades near the deal price.

    The buyout is the single biggest force setting SLP's price now.

  • Agentic AI layer built with NVIDIA BioNeMo Simulations Plus is building an AI 'agent' layer for its Composer platform using NVIDIA's BioNeMo toolkit, expanding a May 2026 partnership. It aims to speed up drug-modeling workflows while keeping scientific results traceable. This supports the company's long-term technology story, though the pending buyout now matters more for the share price.

    It shows the technology value underpinning the company being acquired.

  • Q3 swing to profit on no impairment charge Simulations Plus reported Q3 net income of $3.58 million versus a $67.32 million loss a year earlier, which had included a $77.22 million write-down. Revenue rose 7% to $21.89 million, but adjusted earnings fell to $0.30 a share from $0.45. Profitability improved, yet the core business still shows pressure.

    It gives the latest financial health picture behind the buyout.

  • Investor investigation revives old accounting worries Johnson Fistel is investigating Simulations Plus over a 2025 revenue guidance cut, a large net loss, and the dismissal of auditor Grant Thornton, which flagged unresolved segment-reporting and internal-control issues. These are old disclosures, but the probe keeps the accounting overhang in view and is a real counterweight to the buyout news.

    It is the main risk factor that could complicate or delay the deal.

Latest
▲3▼1

Altaris buyout at $18.50 cash anchors SLP; old accounting probe resurfaces

  • Altaris to buy SLP for $375M all-cash Altaris agreed to acquire Simulations Plus for about $375 million, or $18.50 a share in cash — a 26% premium to the 60-day average price. The board unanimously approved it, with closing expected in late 2026. This sets a firm floor under the stock and is the main reason it trades near the deal price.

    The buyout is the single biggest force setting SLP's price now.

  • Agentic AI layer built with NVIDIA BioNeMo Simulations Plus is building an AI 'agent' layer for its Composer platform using NVIDIA's BioNeMo toolkit, expanding a May 2026 partnership. It aims to speed up drug-modeling workflows while keeping scientific results traceable. This supports the company's long-term technology story, though the pending buyout now matters more for the share price.

    It shows the technology value underpinning the company being acquired.

  • Q3 swing to profit on no impairment charge Simulations Plus reported Q3 net income of $3.58 million versus a $67.32 million loss a year earlier, which had included a $77.22 million write-down. Revenue rose 7% to $21.89 million, but adjusted earnings fell to $0.30 a share from $0.45. Profitability improved, yet the core business still shows pressure.

    It gives the latest financial health picture behind the buyout.

  • Investor investigation revives old accounting worries Johnson Fistel is investigating Simulations Plus over a 2025 revenue guidance cut, a large net loss, and the dismissal of auditor Grant Thornton, which flagged unresolved segment-reporting and internal-control issues. These are old disclosures, but the probe keeps the accounting overhang in view and is a real counterweight to the buyout news.

    It is the main risk factor that could complicate or delay the deal.

Veeva Systems Inc Class A (VEEV)

Q3 2026
▲3

Veeva beats Q2, raises guidance, and lands Eli Lilly as global CRM client

  • Eli Lilly commits to Veeva Vault CRM globally Eli Lilly will roll out Veeva's Vault CRM across its global operations. This is a big customer win: it shows top drugmakers will put critical sales software on Veeva's platform, which supports future subscription and services revenue.

    A major new customer commitment directly supports Veeva's growth outlook and is a core reason the stock is moving.

  • Q2 earnings and revenue beat estimates Veeva reported quarterly profit of $2.35 per share and revenue of $928 million, both above analyst expectations. Revenue grew 17.6% from a year earlier. Beating estimates shows the business is performing better than Wall Street expected, which pushes the stock up.

    The earnings beat is the main new financial event driving the stock higher this period.

  • Full-year guidance raised on AI momentum Management raised full-year revenue and profit guidance, citing AI as a new growth chapter. Vault CRM had its best quarter ever, and Veeva Falcon is accelerating. Higher guidance tells investors future results will be stronger than previously thought, lifting the stock.

    Raised guidance changes forward expectations, a key driver of the stock's move.

  • Leadership change and valuation caution Veeva's president and chief customer officer will leave in October, with a new sales and services head named. Also, the stock's price-to-earnings ratio of 45 is well above the industry average, leaving little room for error if growth slows.

    This is the real counterweight: a management change and high valuation could limit gains or add risk.

August 2026
▲3

Veeva beats Q2, raises guidance, and lands Eli Lilly as global CRM client

  • Eli Lilly commits to Veeva Vault CRM globally Eli Lilly will roll out Veeva's Vault CRM across its global operations. This is a big customer win: it shows top drugmakers will put critical sales software on Veeva's platform, which supports future subscription and services revenue.

    A major new customer commitment directly supports Veeva's growth outlook and is a core reason the stock is moving.

  • Q2 earnings and revenue beat estimates Veeva reported quarterly profit of $2.35 per share and revenue of $928 million, both above analyst expectations. Revenue grew 17.6% from a year earlier. Beating estimates shows the business is performing better than Wall Street expected, which pushes the stock up.

    The earnings beat is the main new financial event driving the stock higher this period.

  • Full-year guidance raised on AI momentum Management raised full-year revenue and profit guidance, citing AI as a new growth chapter. Vault CRM had its best quarter ever, and Veeva Falcon is accelerating. Higher guidance tells investors future results will be stronger than previously thought, lifting the stock.

    Raised guidance changes forward expectations, a key driver of the stock's move.

  • Leadership change and valuation caution Veeva's president and chief customer officer will leave in October, with a new sales and services head named. Also, the stock's price-to-earnings ratio of 45 is well above the industry average, leaving little room for error if growth slows.

    This is the real counterweight: a management change and high valuation could limit gains or add risk.

Latest
▲3

Veeva beats Q2, raises guidance, and lands Eli Lilly as global CRM client

  • Eli Lilly commits to Veeva Vault CRM globally Eli Lilly will roll out Veeva's Vault CRM across its global operations. This is a big customer win: it shows top drugmakers will put critical sales software on Veeva's platform, which supports future subscription and services revenue.

    A major new customer commitment directly supports Veeva's growth outlook and is a core reason the stock is moving.

  • Q2 earnings and revenue beat estimates Veeva reported quarterly profit of $2.35 per share and revenue of $928 million, both above analyst expectations. Revenue grew 17.6% from a year earlier. Beating estimates shows the business is performing better than Wall Street expected, which pushes the stock up.

    The earnings beat is the main new financial event driving the stock higher this period.

  • Full-year guidance raised on AI momentum Management raised full-year revenue and profit guidance, citing AI as a new growth chapter. Vault CRM had its best quarter ever, and Veeva Falcon is accelerating. Higher guidance tells investors future results will be stronger than previously thought, lifting the stock.

    Raised guidance changes forward expectations, a key driver of the stock's move.

  • Leadership change and valuation caution Veeva's president and chief customer officer will leave in October, with a new sales and services head named. Also, the stock's price-to-earnings ratio of 45 is well above the industry average, leaving little room for error if growth slows.

    This is the real counterweight: a management change and high valuation could limit gains or add risk.

Q2 2026
▲3▼1

Veeva's AI Push and Earnings Beat Drive Gains, Fed Clouds Outlook

  • AI product launches and acquisition Veeva acquired Copli and launched Veeva Falcon MLR, an AI tool that automates medical, legal, and regulatory reviews, cutting manual work by over 70%. This expands Veeva's AI offerings and could boost future sales, pushing the stock up.

    This is a major new product and acquisition that directly drives VEEV's growth prospects.

  • Strong Q1 earnings and raised guidance Veeva beat earnings and revenue estimates, with subscription revenue up 15% and total revenue up 16%. The company raised full-year revenue guidance, signaling confidence. This positive financial performance supports a higher stock price.

    Earnings beat and guidance raise are key fundamental drivers of the stock's recent rise.

  • Fed signals no rate cuts, pressuring software stocks The Federal Reserve held rates steady and removed expectations for a 2026 cut, even hinting at a possible hike. Higher rates reduce the present value of future profits, which hurts software companies like Veeva. The stock fell 4.7% on the news.

    Monetary policy directly affects VEEV's valuation as a growth stock.

  • Nvidia CEO endorses AI's benefit to software Jensen Huang said AI will improve software companies, not replace them, naming Veeva as a potential winner. This endorsement boosts investor confidence in Veeva's AI strategy and long-term demand.

    High-profile support for AI in software can lift sentiment and demand for VEEV.

June 2026
▲3▼1

Veeva's AI Push and Earnings Beat Drive Gains, Fed Clouds Outlook

  • AI product launches and acquisition Veeva acquired Copli and launched Veeva Falcon MLR, an AI tool that automates medical, legal, and regulatory reviews, cutting manual work by over 70%. This expands Veeva's AI offerings and could boost future sales, pushing the stock up.

    This is a major new product and acquisition that directly drives VEEV's growth prospects.

  • Strong Q1 earnings and raised guidance Veeva beat earnings and revenue estimates, with subscription revenue up 15% and total revenue up 16%. The company raised full-year revenue guidance, signaling confidence. This positive financial performance supports a higher stock price.

    Earnings beat and guidance raise are key fundamental drivers of the stock's recent rise.

  • Fed signals no rate cuts, pressuring software stocks The Federal Reserve held rates steady and removed expectations for a 2026 cut, even hinting at a possible hike. Higher rates reduce the present value of future profits, which hurts software companies like Veeva. The stock fell 4.7% on the news.

    Monetary policy directly affects VEEV's valuation as a growth stock.

  • Nvidia CEO endorses AI's benefit to software Jensen Huang said AI will improve software companies, not replace them, naming Veeva as a potential winner. This endorsement boosts investor confidence in Veeva's AI strategy and long-term demand.

    High-profile support for AI in software can lift sentiment and demand for VEEV.

▲3▼1

Veeva's AI Push and Earnings Beat Drive Gains, Fed Clouds Outlook

  • AI product launches and acquisition Veeva acquired Copli and launched Veeva Falcon MLR, an AI tool that automates medical, legal, and regulatory reviews, cutting manual work by over 70%. This expands Veeva's AI offerings and could boost future sales, pushing the stock up.

    This is a major new product and acquisition that directly drives VEEV's growth prospects.

  • Strong Q1 earnings and raised guidance Veeva beat earnings and revenue estimates, with subscription revenue up 15% and total revenue up 16%. The company raised full-year revenue guidance, signaling confidence. This positive financial performance supports a higher stock price.

    Earnings beat and guidance raise are key fundamental drivers of the stock's recent rise.

  • Fed signals no rate cuts, pressuring software stocks The Federal Reserve held rates steady and removed expectations for a 2026 cut, even hinting at a possible hike. Higher rates reduce the present value of future profits, which hurts software companies like Veeva. The stock fell 4.7% on the news.

    Monetary policy directly affects VEEV's valuation as a growth stock.

  • Nvidia CEO endorses AI's benefit to software Jensen Huang said AI will improve software companies, not replace them, naming Veeva as a potential winner. This endorsement boosts investor confidence in Veeva's AI strategy and long-term demand.

    High-profile support for AI in software can lift sentiment and demand for VEEV.

© 2026 MarketDXWhy